Top 20 block­buster drugs in the late-stage pipeline — Eval­u­atePhar­ma

Every time news hits about an­oth­er biosim­i­lar to Hu­mi­ra, an­a­lysts are re­mind­ed that Ab­b­Vie $AB­BV is liv­ing on bor­rowed time. Ever since the big split with Ab­bott, the com­pa­ny has been wheel­ing and deal­ing its way in­to Phase III in a huge gam­ble that it can hold off copy­cats long enough to field a slate of drugs ca­pa­ble of re­plac­ing a ther­a­py that now de­liv­ers $16 bil­lion a year.

The new list from Eval­u­atePhar­ma on the top 20 late-stage drugs in the pipeline — in­clud­ed in its big an­nu­al re­port on the in­dus­try — un­der­scores just how hard that is, and al­so how much progress Ab­b­Vie is mak­ing.

Ab­b­Vie has 4 drugs in late-stage de­vel­op­ment that fall in the top 20, more than any oth­er com­pa­ny on the list. These drugs range from Ro­va-T (with a 2022 sales es­ti­mate of $1.5 bil­lion), fol­lowed by elagolix ($1.5 bil­lion), its promis­ing JAK1 in­hibitor ABT-494 ($1.2 bil­lion) and gle­capre­vir/pi­brentasvir ($1.2 bil­lion), which has been wide­ly ig­nored re­cent­ly as it made its way through late-stage hep C tri­als just as the mar­ket has be­gun to shrink fast.

Risky? The $5.4 bil­lion of col­lec­tive­ly pro­ject­ed an­nu­al rev­enue in­cludes a can­cer drug that many be­lieve Ab­b­Vie over­spent on in buy­ing Stem­cen­trx. And even if they all suc­ceed, it’s on­ly a por­tion of what Hu­mi­ra is good for, as long as they can hold on to patent pro­tec­tion.

If Eval­u­ate is right, Gilead $GILD could eas­i­ly ri­val Ab­b­Vie’s pack­age just with its lat­est cock­tail for HIV, adding bicte­gravir to the mix with po­ten­tial an­nu­al sales of $4.4 bil­lion — the high­est mon­ey­mak­er on the list and the on­ly one field­ed by Gilead, which has been hav­ing some trou­ble in the clin­ic over the past year.

No­vo Nordisk al­so helps demon­strate why one big drug in a big dis­ease field can be worth more than a host of small­er ther­a­pies. Its GLP-1 en­try semaglu­tide comes with $2.2 bil­lion in peak sales fore­cast.

J&J $JNJ comes in num­ber two in terms of to­tal num­ber of po­ten­tial block­busters, with three prod­ucts on the list: apa­lu­tamide ($1.6 bil­lion; re­mem­ber ARN-509 from Aragon?) fol­lowed by guselkum­ab ($1.5 bil­lion) and sirukum­ab ($1.1 bil­lion).

Two of the big biotechs, Bio­gen $BI­IB and Cel­gene $CELG, are rep­re­sent­ed here by ad­u­canum­ab — an­oth­er high-risk, high-re­ward play aimed at Alzheimer’s pegged at $1.5 bil­lion — and ozan­i­mod, sucked up in­to Cel­gene’s pipeline dur­ing one of the longest deal sprees in in­dus­try his­to­ry. Ozan­i­mod is as­signed 2022 po­ten­tial sales of $1.8 bil­lion.

In­cyte $IN­CY could ri­val ozan­i­mod sales though, with a sim­i­lar amount pro­vid­ed for epaca­do­stat, its lead­ing IDO1 drug which has fig­ured promi­nent­ly in the news re­cent­ly.

Not every­one is like­ly to agree that Kite’s lead CAR-T $KITE is worth twice the an­nu­al sales of No­var­tis’ leader $NVS in the field, as Eval­u­ate lists these fig­ures. But they’ll like­ly be giv­en plen­ty of op­por­tu­ni­ty to demon­strate their po­ten­tial fol­low­ing loom­ing PDU­FA dates on both.

As­traZeneca $AZN, which bad­ly needs to start gen­er­at­ing more rev­enue, is down to one on the list, now that dur­val­um­ab was ap­proved as the 5th PD-(L)1 check­point. But the CT­LA-4 cat­e­go­ry has been the cause of some fret­ting late­ly, and the drug falls just shy of block­buster sta­tus on the list.

Down­load the full re­port here: World Pre­view 2017, Out­look to 2022

De­vel­op­ment of the Next Gen­er­a­tion NKG2D CAR T-cell Man­u­fac­tur­ing Process

Celyad’s view on developing and delivering a CAR T-cell therapy with multi-tumor specificity combined with cell manufacturing success
Overview
Transitioning potential therapeutic assets from academia into the commercial environment is an exercise that is largely underappreciated by stakeholders, except for drug developers themselves. The promise of preclinical or early clinical results drives enthusiasm, but the pragmatic delivery of a therapy outside of small, local testing is most often a major challenge for drug developers especially, including among other things, the manufacturing challenges that surround the production of just-in-time and personalized autologous cell therapy products.

Paul Hudson, Getty Images

UP­DAT­ED: Sanofi CEO Hud­son lays out new R&D fo­cus — chop­ping di­a­betes, car­dio and slash­ing $2B-plus costs in sur­gi­cal dis­sec­tion

Earlier on Monday, new Sanofi CEO Paul Hudson baited the hook on his upcoming strategy presentation Tuesday with a tell-tale deal to buy Synthorx for $2.5 billion. That fits squarely with hints that he’s pointing the company to a bigger future in oncology, which also squares with a major industry tilt.

In a big reveal later in the day, though, Hudson offered a slate of stunners on his plans to surgically dissect and reassemble the portfoloio, saying that the company is dropping cardio and diabetes research — which covers two of its biggest franchise arenas. Sanofi missed the boat on developing new diabetes drugs, and now it’s pulling out entirely. As part of the pullback, it’s dropping efpeglenatide, their once-weekly GLP-1 injection for diabetes.

“To be out of cardiovascular and diabetes is not easy for a company like ours with an incredibly proud history,” Hudson said on a call with reporters, according to the Wall Street Journal. “As tough a choice as that is, we’re making that choice.”

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 67,300+ biopharma pros reading Endpoints daily — and it's free.

Roger Perlmutter, Merck

#ASH19: Here’s why Mer­ck is pay­ing $2.7B to­day to grab Ar­Qule and its next-gen BTK drug, lin­ing up Eli Lil­ly ri­val­ry

Just a few months after making a splash at the European Hematology Association scientific confab with an early snapshot of positive data for their BTK inhibitor ARQ 531, ArQule has won a $2.7 billion buyout deal from Merck.

Merck is scooping up a next-gen BTK drug — which is making a splash at ASH today — from ArQule in an M&A pact set at $20 a share $ARQL. That’s more than twice Friday’s $9.66 close. And Merck R&D chief Roger Perlmutter heralded a deal that nets “multiple clinical-stage oral kinase inhibitors.”

This is the second biotech buyout pact today, marking a brisk tempo of M&A deals in the lead-up to the big JP Morgan gathering in mid-January. It’s no surprise the acquisitions are both for cancer drugs, where Sanofi will try to make its mark while Merck beefs up a stellar oncology franchise. And bolt-ons are all the rage at the major pharma players, which you could also see in Novartis’ recent $9.7 billion MedCo buyout.

ArQule — which comes out on top after their original lead drug foundered in Phase III — highlighted early data on ‘531 at EHA from a group of 6 chronic lymphocytic leukemia patients who got the 65 mg dose. Four of them experienced a partial response — a big advance for a company that failed with earlier attempts.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 67,300+ biopharma pros reading Endpoints daily — and it's free.

Paul Hudson, Sanofi

Paul Hud­son promis­es a bright new fu­ture at Sanofi, kick­ing loose me-too drugs and fo­cus­ing on land­mark ad­vances. But can he de­liv­er?

Paul Hudson was on a mission Tuesday morning as he stood up to address Sanofi’s new R&D and business strategy.

Still fresh into the job, the new CEO set out to convince his audience — including the legions of nervous staffers inevitably devoting much of their day to listening in — that the pharma giant is shedding the layers of bureaucracy that had held them back from making progress in the past, dropping the duds in the pipeline and reprioritizing a more narrow set of experimental drugs that were promised as first-in-class or best-in-class.  The company, he added, is now positioned to “go after other opportunities” that could offer a transformational approach to treating its core diseases.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 67,300+ biopharma pros reading Endpoints daily — and it's free.

Am­gen puts its foot down in shiny new South San Fran­cis­co hub as it re­or­ga­nizes R&D ops

Amgen has signed up to be AbbVie’s neighbor in South San Francisco as it moves into a nine-story R&D facility in the booming biotech hub.

The arrangement gives Amgen 240,000 square feet of space on the Gateway of Pacific Campus, just a few minutes drive from its current digs at Oyster Point. The new hub will open in 2022 and house the big biotech’s Bay Area employees working on cardiometabolic, inflammation and oncology research.

Ab­b­Vie, Scripps ex­pand part­ner­ship, for­ti­fy fo­cus on can­cer drugs

Scripps and AbbVie go way back. Research conducted in the lab of Scripps scientist Richard Lerner led to the discovery of Humira. The antibody, approved by the FDA in 2002 and sold by AbbVie, went on to become the world’s bestselling treatment. In 2018, the drugmaker and the non-profit organization signed a pact focused on developing cancer treatments — and now, the scope of that partnership has broadened to encompass a range of diseases, including immunological and neurological conditions.

South Ko­rea jails 3 Sam­sung ex­ecs for de­stroy­ing ev­i­dence in Bi­o­Log­ics probe

Three Samsung executives in Korea are going to jail.

The convictions came in what prosecutors had billed as “biggest crime of evidence destruction in the history of South Korea”: a case of alleged corporate intrigue that was thrown open when investigators found what was hidden beneath the floor of a Samsung BioLogics plant. Eight employees in total were found guilty of evidence tampering and the three executives were each sentenced to up to two years in prison.

Nick Plugis, Avak Kahvejian, Cristina Rondinone, Milind Kamkolkar and Chad Nusbaum. (Cellarity)

Cel­lar­i­ty, Flag­ship's $50M bet on net­work bi­ol­o­gy, mar­ries ma­chine learn­ing and sin­gle-cell tech for drug dis­cov­ery

Cellarity started with a simple — but far from easy — idea that Avak Kahvejian and his team were floating around at Flagship Pioneering: to digitally encode a cell.

As he and his senior associate Nick Plugis dug deeper into the concept, they found that most of the models others have developed take a bottom-up approach, where they assemble the molecules inside cells and the connections between them from scratch. What if they opt for a top-down approach, aided by single-cell transcriptomics and machine learning, to gauge the behavior of the entire cellular network?

Sanofi’s big week in­cludes a promis­ing PhI­II for an or­phan dis­ease drug, with plans for a pitch to the FDA

The biopharma R&D food chain is paying off with a plan at Sanofi to pitch regulators on a new drug for an orphan disease called cold agglutinin disease.

The pharma giant ushered out a statement Tuesday morning — after it spelled out plans to radically restructure the company, abandoning cardio and diabetes research altogether — saying that their C1s inhibitor sutimlimab had cleared the pivotal study.